GFRAL and obesity due to melanocortin 4 receptor deficiency: As previously mentioned, GFRAL could also be targeted with an antagonist, to inhibit GDF15/GFRAL signalling, and for the treatment of different conditions such as cachexia, anorexia, or chemotherapy‐induced nausea and vomiting (CINV).[42, 43, 44] Despite previous attempts to treat obesity through GFRAL agonists, the studies on antagonists are lagging behind their agonist counterpart, and interest by pharmacological companies seem to be less pronounced.